2013年第三季度台湾制药及保健市场研究报告——Taiwan Pharmaceuticals and Healthcare Report Q3 2013

纸介版价格:美元/篇 页数:120页上传日期:2013-07-11
电子版价格:1295美元/篇
纸介版+电子版价格:美元 附件下载:               
关键字: |Pharmaceuticals|Healthcare|

2013-5-22


Abstract

BMI View: Taiwan will continue to represent a modestly attractive proposition for drug manufactures. Our
view is based on factors such as the maturity of its pharmaceutical market, government encouragement of
generic medicines and authorities desire to reduce unnecessary use of medicines. For example, the Bureau
of National Health Insurance (BNHI) in Taiwan is cracking down on prescription drugs waste by tightening
its oversight of prescription drug distribution. Therefore, we envisage that main drivers of the Taiwanese
pharmaceutical market development will be volume- based, thus not necessarily translating into strong
value gains, especially given the pending changes to reimbursement.
Headline Expenditure Projections
■ Pharmaceuticals: TWD142.50bn (US$4.82bn) in 2012 to TWD149.90bn (US$5.12bn) in 2013; +5.2%
in local currency terms and +6.2% in US dollar terms. Forecast broadly in line with previous quarter's
projections.
■ Healthcare: TWD975.96bn (US$32.99bn) in 2012 to TWD1,023bn (US$34.93bn) in 2013; +4.9% in
local currency terms and +5.9% in US dollar terms. Forecast broadly in line with previous quarter's
projections.

Table of Contents

BMI Industry View ... 7
SWOT  9
Political . 11
Economic ..... 12
Business Environment  14
Industry Forecast .. 15
Pharmaceutical Market Forecast .... 15
Table: Taiwan Pharmaceutical Sales, Historical Data and Forecasts. 16
Healthcare Market Forecast .... 17
Table: Taiwan Healthcare Expenditure Trends, Historical Data and Forecasts    . . 18
Table: Taiwan Government Healthcare Expenditure Trends, Historical Data and Forecasts 19
Table: Taiwan Private Healthcare Expenditure Trends, Historical Data and Forecasts  . . 19
Prescription Drug Market Forecast  21
Table: Taiwan Prescription Drug Market Indicators, Historical Data and Forecasts   23
Patented Drug Market Forecast ..... 23
Table: Top 10 Pharmaceuticals In Taiwan According To BNHI Expenditure During 2008 . . . 24
Table: Taiwan Patented Drug Market Indicators, Historical Data and Forecasts    25
Generic Drug Market Forecast  25
Table: Taiwan Generics Drug Market Indicators, Historical Data and Forecasts    27
OTC Medicine Market Forecast ..... 27
Table: Taiwan Over-The-Counter (OTC) Medicine Market Indicators, Historical Data and Forecasts     . . 29
Pharmaceutical Trade  30
Table: Taiwan Pharmaceutical Trade Data And Forecasts (US$mn). . 32
Table: Taiwan Pharmaceutical Trade Data And Forecasts (TWDmn)32
Other Healthcare Data ..... 32
Key Risks To BMI's Forecast Scenario ... 34
Macroeconomic Forecasts ..... 35
Economic Analysis ..... 35
Erosion Of Tech Competiveness .... 37
Politics Behind Hesitation Towards Chinese Investment .. 38
Labour Market Overly Rigid, Reform Unlikely ... 39
Demographic Decline To Aggravate Labour Market Woes ..... 40
Growth Projections Downgraded .. 41
Expenditure Breakdown .. 41
Private Consumption  41
Government Consumption  41
Gross Fixed Capital Formation .... 42
Net Exports . 42
Industry Risk Reward Ratings  43
Asia Pacific Risk/Reward Ratings ... 43
Taiwan Risk/Reward Ratings ... 48
Market Overview ... 50
Industry Trends And Developments .. 51
Table: Sources of Financing    55
Table: Taiwan Insurance Coverage  57
Regulatory Development .. 65
Table: Medicine Categories In Taiwan . 66
Table: Examples Of Controlled Drugs In Taiwan     . . 67
Table: Reimbursement System in Taiwan. . . 74
Table: Drug Reimbursement Principles 76
Table: BNHI Spending By Type Of Outpatient Claims, As Percentage Of Total    . . 77
Competitive Landscape .... 80
Table: Western & TCM Manufacturers, 2006-10     . . 80
Table: Pharmaceutical Output Value by Type, 2002-10 (US$mn) . 81
Table: Top-20 Pharmaceutical & Biotechnology Firms In Taiwan According To Market Capitalisation (US$mn)  . . 81
Table: TGPA Members, 2012   . . . 83
Table: Corporate Members Of Taiwan's IRPMA, 2012    86
Table: Western Drug Distributors 2006-1087
Table: Pharmacies, 2006-10    88
Company Profile .... 90
Yung Shin Pharmaceutical (YSP) .... 90
ScinoPharma Taiwan . 93
Empax Pharma ... 96
TaiGen .. 98
Pfizer .. 100
Sanofi .. 103
GlaxoSmithKline ..... 105
Novartis ..... 108
Merck & Co  111
Glossary ... 114
Methodology .. 116
Pharmaceutical Expenditure Forecast Model .. 116
Healthcare Expenditure Forecast Model ... 116
Notes On Methodology .. 117
Risk/Reward Ratings Methodology .... 118
Ratings Overview ... 119
Table: Pharmaceutical Risk/Reward Ratings Indicators   . . 119
Indicator Weightings .... 120

定购方法
① 注册订购:
点击在线订购进行报告订购
我们的服务人员将在24小时内与您联系。

② 电话订购:
拔打电话
北京:400 0090050   010-82863481
24小时:13436696826
传真:010-82601570

上海:021-64871266
021-64872612
24小时:13524982235
传真:021-64872324

签订协议
可从网上下载报告订购表或由我们传真报告订购表或订购协议。
传真:010-82601570

付款方式
① 通过银行转帐的形式支付报告购买款项
② 我们收到款项后,24小时内快递报告或者发送报告邮件

③ 款项到帐后快递发票

银行电汇:
北京:
开户行:
上海浦东发展银行北京知春路支行
帐号:91170154740001300
户名:北京佐思信息咨询有限责任公司
外币汇款账户信息:
BENEFICIARY’S BANK (受益人银行名称):
SHANGHAI PUDONG DEVELOPMENT BANK, H.O. SHANGHAI, CHINA
SWIFT:
SPDBCNSH390
BENEFICIARY’S A/C NO. (受益人帐号):
911 701 547 4000 1300
BENEFICIARY’S NAME(受益人名称):
OKOKOK(ZUOSI) Information Consulting CO.,LTD
COMPANY ADDRESS:
Room 1008, Tower A2, Longrange World Office Building, No.18 Suzhou Street, Haidian District, Beijing China
REMARKS(附言):
SHANGHAI PUDONG DEVELOPMENT BANK, BEIJING BR.***SUB-BR
在线客服系统